港股异动丨轩竹生物逆势大涨17%创新高 上市三日股价较发行价已累涨近2倍！

Core Viewpoint - The Hong Kong stock market experienced a significant decline, with the Hang Seng Index dropping over 4%, reaching a new low in over a month. In contrast, Xuan Bamboo Biotech (2575.HK), spun off from Sihuan Pharmaceutical, saw its stock price surge by 17.1% to HKD 33.96, marking a new high since its IPO [1]. Company Overview - Xuan Bamboo Biotech is an innovative Chinese biopharmaceutical company focused on improving patient health and life through a deep understanding of the Chinese pharmaceutical industry and its unique clinical needs [1]. - Since its acquisition by Sihuan Pharmaceutical in 2008, Xuan Bamboo has established a comprehensive internal R&D platform that supports the development of a diverse and balanced pipeline of drug candidates [1]. Financial Performance - The stock price of Xuan Bamboo Biotech has increased by 192.76% from its IPO price of HKD 11.6, just three trading days after its debut on the Hong Kong Stock Exchange [1]. Drug Development Pipeline - Xuan Bamboo Biotech currently has over ten drug assets actively in development, targeting diseases such as digestive system disorders, tumors, and non-alcoholic fatty liver disease (NASH) [1]. - The company has three assets approved for New Drug Application (NDA), one project in the NDA registration stage, one in Phase III clinical trials, four in Phase I clinical trials, and five that have received Investigational New Drug (IND) approval [1].